ADMA Q3'26 Earnings: EPS estimate is 0.20 USD

What happened

ADMA Biologics is scheduled to report its third-quarter 2026 results on November 4 after the market closes, with disclosure expected at 4:05 p.m. ET. The supplied estimates are revenue of $138.11 million and earnings per share, or profit allocated to each share, of $0.20.

Confirmed

Global impact / market context

The estimates give investors a reference point for judging the report: revenue above or below $138.11 million could indicate stronger or weaker sales, while earnings per share versus $0.20 could signal changes in profitability. The figures are expectations, not reported results.

Analyst inference

The supplied history shows quarterly revenue estimates and reported figures have not always matched, and earnings per share has also been above or below estimates. That record makes the upcoming comparison relevant, but the article provides no explanation for past differences or expected market reaction.

Analyst inference

What to watch

1. On November 4 after the market closes, compare reported revenue with the $138.11 million estimate to see whether sales came in above or below expectations. Analyst inference
2. Compare reported earnings per share with the $0.20 estimate; the article gives the expected figure but does not provide the actual result yet. Analyst inference
3. The article schedules disclosure for 4:05 p.m. ET and supplies no company outlook or reason for prior estimate differences; check whether results add such details. Analyst inference

Evidence

• Original source link unavailable